Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
|Articles|February 1, 2012

Applied Clinical Trials

  • Applied Clinical Trials-02-01-2012
  • Volume 21
  • Issue 2

Unexpected Trend in Global Subject Enrollment

Medidata Solutions

Clinical R&D organizations have placed increasing emphasis over the past decade on finding clinical research subjects in emerging global regions including Asia Pacific, Eastern Europe, and South America. This emphasis has multiple business drivers, but perhaps the most prominent is the ever-increasing competition for subjects.

Interestingly, enrollment metrics compiled from the Medidata Insights metrics warehouse—comprising close to 1,700 studies from 50 R&D organizations—tell a somewhat different story. The graph displays the relative proportion of trial subjects recruited annually from each of four global regions, from 2008 through 2011. In particular, the trend in proportion of subjects recruited from Eastern Europe and Asia Pacific appears to be flat or even slightly down over this four-year period, while the trends for North America and Western Europe are flat or even slightly up over the same period.

North American enrollment rose slightly, while Asian Pacific slightly fell.

It is not clear to what extent this trend will continue. What do you think the main drivers are? Can it primarily be attributed to the economic slowdown? Have sponsors concluded that conducting studies in these emerging markets is too complicated? Stay tuned as we will definitely keep an eye on this trend to see how it plays out in 2012.

Each month, an Insights metric to highlight emerging trends in clinical development will be featured. For more on the industry benchmarks and clinical business analytics capabilities of Medidata Insights, please visit http://mdsol.com/insights. —Medidata Solutions, www.mdsol.com

Articles in this issue

almost 15 years ago

Pharmacovigilance Alliances

almost 15 years ago

PPD Trains CRAs in Three Dimensions

almost 15 years ago

Business and News Update February 2012

almost 15 years ago

Looking Beyond the Euro Turmoil

almost 15 years ago

Give the Patient a Clear Voice

almost 15 years ago

Strategic Partnership

almost 15 years ago

Leveraging the Transition

Related to this article

What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.